Demographic and clinical characteristics distribution according to nontuberculous mycobacteria (NTM) status (no NTM versus single growth versus colonisation) and adjusted odds ratios (95% CI) for the association with any NTM growth (composite of single growth and colonisation)
| No NTM | NTM single growth | NTM colonisation | p-value# | Adjusted OR¶ (95% CI) | |
| Patients n | 6169 | 75 | 30 | ||
| Age <65 years | 2542 (41.2%) | 40 (53.3%) | 16 (53.3%) | 0.044 | 2.1 (1.4–3.10) |
| Female | 3324 (53.9%) | 52 (69.3%) | 21 (70.0%) | 0.006+ | 1.66 (1.1–2.60) |
| Ethnicity | 0.512 | ||||
| Jews | 5472 (88.7%) | 69 (92.0%) | 28 (93.3%) | Ref. | |
| Arabs | 697 (11.3%) | 6 (8.0%) | 2 (6.7%) | 0.60 (0.28–1.30) | |
| SES | 0.158 | ||||
| Low | 2141 (38.0%) | 19 (26.0%) | 7 (25.0%) | Ref. | |
| Medium | 2333 (41.4%) | 36 (49.3%) | 13 (46.4%) | 1.86 (1.12–3.10) | |
| High | 1162 (20.6%) | 18 (24.7%) | 8 (28.6%) | 1.83 (1.03–3.30) | |
| Macrolide treatment during 2009 | 1351 (21.9%) | 23 (30.7%) | 7 (23.3%) | 0.187 | 0.96 (0.61–1.50) |
| Any antibiotic treatment during 2009 | 4331 (70.2%) | 65 (86.7%) | 26 (86.7%) | 0.001+ | 2.50 (1.30–4.70) |
| Prednisone treatment during 2009 | 1082 (17.5%) | 21 (28.0%) | 9 (30.0%) | 0.013+ | 1.80 (1.15–2.85) |
| Current or past smoking | 2261 (36.7%) | 21 (28.0%) | 5 (16.7%) | 0.024§ | 0.60 (0.37–0.97) |
| Any hospitalisation before 2010 | 3311 (53.7%) | 40 (53.3%) | 20 (66.7%) | 0.362 | 1.20 (0.78–1.80) |
Data are presented as n (%) unless otherwise stated. Risk assesment of acquiring NTM growth and colonisation. SES: socioeconomic status. #: comparison between three groups; ¶: adjusted odds ratio for any growth (composite of single growth and colonisation); +: significant difference after Bonferroni correction between no NTM and NTM single growth; §: significant difference after Bonferroni correction between NTM single growth and NTM colonisation. Bold indicates statistically significant odds ratios.